Archived explainer. For the current picture see today's ALNY page.
ALNYLAM PHARMACEUTIC (ALNY) is down -4.15% in the latest session. Our newswire has captured 2 stories on ALNY across 2 sources in the last 36 hours, with AI sentiment reading bullish (avg 59/100).
Alnylam Pharmaceuticals stock fell 4.15% to $271.39 in morning trading as the stock opened with a small gap down and continued to decline through the session. The move comes amid mixed external signals, including a recent insider sale and ongoing investor sentiment deterioration. While several analysts maintain a Buy rating, the stock's sharp intraday drop reflects broader market caution.
The stock opened at $280.99, down 0.8% from the prior close, and continued to fall throughout the morning, reaching a low of $270.63 before stabilizing slightly. The session saw 0.3 million shares traded, in line with the 3-month average. The decline occurred despite recent analyst activity, including a raised price target from HC Wainwright & Co. to $485 and a reaffirmed Buy rating from B of A and Truist Securities, both of which cut their price targets to $410.
The stock is also preparing for its Q2 2026 earnings webcast, scheduled for 8:30 a.m. ET, which may provide further clarity on the company's financial and operational performance. Meanwhile, Alnylam has continued to advance its neuroscience pipeline, including the initiation of a Phase 2 study for mivelsiran in Down syndrome-associated Alzheimer's.
The stock is trading near its 52-week low of $273.11, with a market cap of $37.6 billion and a P/E ratio of 71.7. Revenue has grown 82.6% in the trailing twelve months, and the company maintains a 12.5% net margin. Beta is at 0.27, indicating low volatility relative to the market. Recent insider activity includes a $1.1 million sale by director David E. Pyott on June 1. Congressional trades show Donald J. Trump has alternated between buying and selling small amounts of the stock in recent months.
Investors will be watching the company's second-quarter 2026 earnings webcast for insights into financial performance and pipeline updates. The stock's near-term direction may also depend on broader market sentiment and further analyst activity.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
The quarter ended June 30 will be discussed at 8:30 a.m. ET, with an archived webcast available on Alnylam's website about two hours later.
Alnylam's robust cash position and GAAP profitability materially reduce investment risk and support pipeline development. Learn why ALNY stock is a buy.
More on ALNY: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ALNY move explainers: 2026-07-20 · 2026-07-17